tradingkey.logo
搜索

Grail Inc

GRAL
添加自选
65.148USD
-1.422-2.14%
交易中 美东报价延迟15分钟
2.68B总市值
亏损市盈率 TTM

Grail Inc

65.148
-1.422-2.14%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.14%

5天

+2.21%

1月

-3.04%

6月

-29.08%

今年开始到现在

-23.88%

1年

+41.09%

关键数据
65.560今开
67.460最高
201.42K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.49%换手率
66.570昨收
65.025最低
9.50M成交额
亏损市盈率静
1.07市净率
0.00%股息率 TTM
-13.99%ROA
118.84052周最高
0.36量比
-2.03B净利润
41.13M总股本
-10.3076每股收益TTM
--Beta
-16.09%ROE
29.95052周最低
3.66%振幅
-35.08%毛利率
2.68B总市值
-1.43回报/风险
4.74%风险率

TradingKey Grail Inc股票评分

单位: USD 更新时间: 2026-06-25

操作建议

Grail Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名71/387位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价64.27。中期看,股价处于上升通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Grail Inc评分

相关信息

行业排名
71 / 387
全市场排名
178 / 4567
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Grail Inc亮点

亮点风险
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
业绩高增长
公司营业收入稳步增长,连续3年增长58.07%
估值低估
公司最新PE估值-6.46,处于3年历史低位
机构加仓
最新机构持股33.74M股,环比增加4.97%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓,最新持仓市值22.82K

分析师目标

根据 9 位分析师
买入
评级
64.266
目标均价
+5.16%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Grail Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Grail Inc简介

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代码GRAL
公司Grail Inc
CEORagusa (Robert)
网址https://grail.com/

常见问题

Grail Inc(GRAL)的当前股价是多少?

Grail Inc(GRAL)的当前股价是 66.57。

Grail Inc的股票代码是什么?

Grail Inc的股票代码是GRAL。

Grail Inc股票的52周最高点是多少?

Grail Inc股票的52周最高点是118.84。

Grail Inc股票的52周最低点是多少?

Grail Inc股票的52周最低点是29.95。

Grail Inc的市值是多少?

Grail Inc的市值是2.86B。

现在Grail Inc(GRAL)的股票是买入、持有还是卖出?

根据分析师评级,Grail Inc(GRAL)的总体评级为买入,目标价格为64.27。

Grail Inc(GRAL)股票的每股收益(EPS TTM)是多少

Grail Inc(GRAL)股票的每股收益(EPS TTM)是-11.11。
KeyAI